

08-02-1999

FORM PTO-1595  
1-31-92

RECORDATION  
PA




DEPARTMENT OF COMMERCE  
Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the.

101106251

1. Name of conveying party(ies):  
Alcon Pharmaceuticals, Inc. *MRO 7-29-99*  
Additional name(s) of conveying party(ies) attached?  Yes  No

2. Name and address of receiving party(ies):  
Name: Falcon Pharmaceuticals, Ltd  
Internal Address: \_\_\_\_\_  
Street Address: 6201 South Freeway  
City: Fort Worth State: TX ZIP: 76134-2099  
Additional name(s) & address(es) attached?  Yes  No



3. Nature of conveyance:  
 Assignment  Merger  
 Security Agreement  Change of Name  
 Other \_\_\_\_\_  
Execution Date: May 26, 1999

4. Application number(s) or patent number(s):  
If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_  
A. Patent Application No. (s) \_\_\_\_\_ B. Patent No. (s)  
5,603,929 and 5,653,972  
Additional numbers attached?  Yes  No

5. Name and address of party to whom correspondence concerning document should be mailed:  
Name: Patrick M. Ryan  
Internal Address: Patent Department Q-148  
ALCON LABORATORIES, INC.  
Street Address: 6201 South Freeway  
City: Fort Worth State: TX ZIP: 76134-2099

6. Total number of applications and patents involved: two (2)  
7. Total fee (37 CFR 3.41).....\$ 80.00  
 Enclosed  
 Authorized to be charged to deposit account  
8. Deposit account number:  
01-0682  
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature  
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.  
Patrick M. Ryan Reg. No. 36,263  
Name of Person Signing Patrick M. Ryan Signature 7/26/99 Date

Total number of pages including cover sheet 2

CMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks  
Box Assignments  
Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

07/30/1999 DMSUYEH 00000361 010682 5603929

01 FC:581 80.00 CH

## ASSIGNMENT

WHEREAS Alcon Pharmaceuticals, Inc. is the owner of record of U.S. Patent Nos. 5,603,929 and 5,653,972 entitled Preserved Ophthalmic Drug Compositions Containing Polymeric Quaternary Ammonium Compounds and all foreign counterparts and all interest in the invention set forth therein;

AND WHEREAS, Falcon Pharmaceuticals, Ltd., a limited partnership organized under the laws of Texas having a principal place of business at 6201, S. Freeway, Fort Worth, Texas 76134 is desirous of acquiring the entire right, title and interest in and to said invention and to any and all Letters Patent of the United States and foreign countries which may be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, Alcon Pharmaceuticals, Inc. does hereby sell, assign and transfer to Falcon Pharmaceuticals, Ltd., its legal representatives, successors, and assigns, effective January 1, 1999, the entire right, title and interest in and to said invention as set forth in U.S. Patent Nos. 5,603,929 and 5,653,972 and to any and all corresponding foreign patents and patents of foreign countries which may be issued for said invention;

UPON SAID CONSIDERATIONS, Alcon Pharmaceuticals, Inc. hereby agrees that it will not execute any writing or do any act whatsoever conflicting with these presents, and that it will, at any time upon request, without further or additional consideration, but at the expense of said assignee, execute such additional assignments and other writings and do such additional acts as said assignee may deem necessary or desirable to perfect the assignee's enjoyment of this grant.

Signature: 

Name: Charles E. Miller, Sr.  
on behalf of Alcon Pharmaceuticals, Inc.

Date: May 26, 1999